Rhythm Pharmaceuticals Inc.

NASDAQ:RYTM   4:00:00 PM EDT
26.77
+1.68 (+6.70%)
5:49:46 PM EDT: $26.77 0.00 (0.00%)
Earnings Announcements

Rhythm Pharmaceuticals Reports Third Quarter Financial Results

Published: 11/08/2022 12:43 GMT
Rhythm Pharmaceuticals Inc. (RYTM) - Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update.
Rhythm Pharmaceuticals - Successfully Completed $140 Million Public Offering With Exercise of Underwriters' Option, Extending Cash Runway Into 2025.
Rhythm Pharmaceuticals - Product Revenues, Net, Relating to Sales of Imcivree Were $4.3 Million for Q3 of 2022, As Compared to $1.0 Million for Q3 of 2021.
Revenue is expected to be $7.25 Million
Adjusted EPS is expected to be -$0.82

Next Quarter Revenue Guidance is expected to be $10.23 Million
Next Quarter EPS Guidance is expected to be -$0.78

More details on our Analysts Page.